Dược Lực Học :
KD7040 demonstrates robust reduction of tactile allodynia in rodent models of pain, including the Chung model (peripheral neuropathy), the Bennet chronic constrictive injury model, and the capsaicin model of central sensitization. Preliminary data from GLP safety pharmacology and toxicology studies have defined a favorable safety profile for entry into the clinic.
Cơ Chế Tác Dụng :
KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
KD7040 is a potent, topically administered, inhibitor of inducible nitric oxide synthase (iNOS) with greater than 200-fold and 2000-fold selectivity over nNOS and eNOS respectively.
Chỉ Định :
For the treatment of pain.
Liều Lượng & Cách Dùng :
Gel - Topical